pidilizumab pidilizumab pidilizumab (formerly ct-011) is a monoclonal antibody being developed by medivation for the treatment of cancer and infectious diseases. pidilizumab was originally thought to bind to the pd-1 immune checkpoint molecule, however, recent evidence suggests that delta-like 1 (dll1) is its primary binding target while binding to pd-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory t cells. pidilizumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetdll1clinical dataatc codenoneidentifierscas number1036730-42-3 ychemspidernoneuniib932paq1bqkeggd10390chemical and physical dataformulac6424h9920n1704o2002s48molar mass144594.83 g·mol−1 clinical trials it had encouraging results by 2011 from phase ii clinical trials for diffuse large b-cell lymphoma. a phase ii open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. a phase i/ii open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome. an add-on trial for multiple myeloma is ongoing.